BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» NHS England slashes Humira spending; U.K., pharma reach deal on new pricing scheme
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
NHS England slashes Humira spending; U.K., pharma reach deal on new pricing scheme
Nov. 28, 2018
By
Nuala Moran
No Comments
LONDON – The National Health Service (NHS) in England is cutting £300 million (US$383 million) off its £400 million annual bill for Humira (adalimumab) after pitting biosimilar manufacturers against each other in a national procurement process.
BioWorld